Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Turkey Again Slashes Drug Prices; Manufacturers And Pharmacists Cry Foul

This article was originally published in The Pink Sheet Daily

Executive Summary

The most recent policies place Turkey in a position where drugs will be sold for 30% to 50% less than the lowest European price, according to the Turkish Association of Research-Based Pharmaceutical Companies.

You may also be interested in...



Nycomed Expands In Turkey, Despite Tough Pharma Environment

Nycomed has gained the rights to market over 10 pharmaceutical products in Turkey, consolidating its position in the country and keeping to its strategy of growth in pharmerging markets.

Nycomed Expands In Turkey, Despite Tough Pharma Environment

Nycomed has gained the rights to market over 10 pharmaceutical products in Turkey, consolidating its position in the country and keeping to its strategy of growth in pharmerging markets.

Abbott, Eli Lilly, Novartis: Emerging Markets Earnings Round Up (Part 1)

Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel